AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, PARALLEL GROUP CLINICAL TRIAL COMPARING THE EFFICACY AND SAFETY OF MYLAN'S INSULIN GLARGINE WITH LANTUS IN TYPE 2 DIABETES MELLITUS PATIENTS

Trial Profile

AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, PARALLEL GROUP CLINICAL TRIAL COMPARING THE EFFICACY AND SAFETY OF MYLAN'S INSULIN GLARGINE WITH LANTUS IN TYPE 2 DIABETES MELLITUS PATIENTS

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms INSTRIDE 2
  • Sponsors Mylan
  • Most Recent Events

    • 13 Jun 2017 Results from the phase III INSTRIDE studies comparing immunogeicity between Mylan's insulin glargine (Basalog) and Lantus in patients with type 1 and 2 diabetes mellitus, presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
    • 13 Jun 2017 Primary endpoint has been met. (Change in HbA1c from baseline to 24 weeks) as per results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top